Trials / Unknown
UnknownNCT02982434
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
Injection of the New Pharmaceutical Composition Containing Botulinum Toxin Into Epicardial Fat Pads to Treat Atrial Fibrillation After Coronary Artery Bypass Grafting
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation · Network
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this prospective randomized double-blind study was to compare the efficacy of new pharmaceutical composition containing botulinum toxin injection in epicardial fat pads for preventing recurrences of atrial tachyarrhythmia in patients with paroxysmal atrial fibrillation undergoing coronary artery bypass grafting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pharmaceutical composition containing botulinum toxin | |
| DRUG | 0.9% normal saline | |
| PROCEDURE | Coronary artery bypass grafting |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-12-01
- Completion
- 2018-02-01
- First posted
- 2016-12-05
- Last updated
- 2016-12-05
Locations
2 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT02982434. Inclusion in this directory is not an endorsement.